Karyopharm Therapeutics Inc. buy Royal Bank of Canada
Start price
03.08.23
/
50%
€1.67
Target price
03.08.24
€3.65
Performance (%)
-49.48%
Price
22.07.24
€0.84
Summary
This prediction is currently active. Massive losses of -49.48% have been the result for the BUY prediction by Royal_Bank_of_Canada. This prediction currently runs until 03.08.24. The prediction end date can be changed by Royal_Bank_of_Canada at any time. Royal_Bank_of_Canada has 50% into this predictionPerformance without dividends (%)
Name | 1w | 1m |
---|---|---|
Karyopharm Therapeutics Inc. | -4.857% | -4.857% |
iShares Core DAX® | -0.543% | 1.491% |
iShares Nasdaq 100 | -2.696% | -1.235% |
iShares Nikkei 225® | -2.863% | 2.491% |
iShares S&P 500 | -1.105% | 0.013% |
Comments by Royal_Bank_of_Canada for this prediction
In the thread Karyopharm Therapeutics Inc. diskutieren
Karyopharm Therapeutics Inc. (NASDAQ: KPTI) had its price target lowered by analysts at Royal Bank of Canada from $5.00 to $4.00. They now have an "outperform" rating on the stock.
Ratings data for KPTI provided by MarketBeat
Stopped prediction by Royal_Bank_of_Canada for Karyopharm Therapeutics Inc.
Karyopharm Therapeutics Inc.
Start price
Target price
Perf. (%)
€0.84
03.11.23
03.11.23
€2.80
03.11.24
03.11.24
0.55%
22.07.24
22.07.24